Loomis, Sayles & Company
MYOK

Loomis, Sayles & Company’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Loomis, Sayles & Company’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-306,686
Closed -$41.8M – 846
2020
Q3 		$41.8M Buy
306,686
+42,774
+16% +$4.55M 0.06% 130
2020
Q2 		$25.5M Sell
263,912
-43,032
-14% -$3.59M 0.04% 183
2020
Q1 		$14.4M Buy
306,944
+1,778
+0.6% +$114K 0.03% 232
2019
Q4 		$22.2M Sell
305,166
-978
-0.3% -$59.3K 0.04% 197
2019
Q3 		$16M Buy
306,144
+34,736
+13% +$1.85M 0.03% 251
2019
Q2 		$13.6M Buy
271,408
+35,529
+15% +$1.73M 0.03% 281
2019
Q1 		$12.3M Buy
+235,879
New +$10.9M 0.02% 316

Loomis, Sayles & Company's MYOK Position: Q4 2020 in Review

Loomis, Sayles & Company sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 306,686 shares — an estimated $41.8M sold.

Loomis, Sayles & Company first reported a position in MYOK in Q1 2019 and held it in 7 quarters. The position peaked at $41.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.

  • Loomis, Sayles & Company reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Loomis, Sayles & Company sold 306,686 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $41.8M.
  • Loomis, Sayles & Company first reported a position in MyoKardia, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • Loomis, Sayles & Company's MyoKardia, Inc. Common Stock position peaked at $41.8M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.

Based on Loomis, Sayles & Company's 13F filing for Q4 2020, filed 12 Feb 2021.